A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml
|
|
- Paulina Aleesha Warner
- 8 years ago
- Views:
Transcription
1 IJCRI 2011;2(9): Rajendiran et al. 16 CASE REPORT OPEN ACCESS A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml Govarthanan Rajendiran, Linda Green, Gurdeep Chhabra ABSTRACT Introduction: Bone metastases from prostate cancer are commonly osteoblastic and can result in disabling skeletal complications and affect quality of life. We report a rare case of prostate cancer presenting with diffuse osteolytic metastases. Case Report: A 65-yearold African American man, with no past medical history or specific urologic symptoms, sought medical attention for non-specific pain symptoms. He had metastatic prostate adenocarcinoma, high PSA level (7242 ng/ml) and extensive osteolytic metastases. After one year of therapy with antiandrogens, zoledronic acid and local radiation, patient was asymptomatic and did not suffer disabling skeletal complications. His PSA level has been stable and less than 1 ng/ml. Conclusion: Prostate cancer can rarely present with diffuse osteolytic metastases. Early initiation of supportive treatment, especially the Govarthanan Rajendiran 1, Linda Green 2, Gurdeep Chhabra 3 Affiliations: 1 PGY-III Pesident/Chief resident, Dept. of Internal Medicine, Prince George s Hospital Center, Maryland, USA; 2 Assistant program director, Dept. of Internal Medicine, Prince George s Hospital Center, Maryland, USA; 3 Hemato-oncologist, Prince George s Hospital Center, Maryland, USA. Corresponding Author: Govarthanan Rajendiran, 3001 Hospital Drive, J-500, 5 TH Floor, Department of Internal Medicine, Cheverly, Maryland, USA 20785; Ph: 1-(301) ; Fax: +1-(301) ; govdocus@gmail.com Received: 28 March 2011 Accepted: 18 August 2011 Published: 01 September 2011 bisphosphonate zoledronic acid, plays a pivotal role in the reduction of disabling skeletal complications. Keywords: Prostate adenocarcinoma, Osteolytic metastases, Androgen deprivation therapy, Skeletal related event, Zoledronic acid Rajendiran G, Green L, Chhabra G. A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. International Journal of Case Reports and Images 2011;2(9): doi: /ijcri cr-5 INTRODUCTION Prostate cancer is the second leading cause of cancer-related death in the United States among men and is one of the most commonly diagnosed cancer in American males [1, 2]. Most prostate cancer related morbidity and mortality are due to advanced disease, when it can metastasize to various regions of the body, most commonly the lymph nodes, bone and lungs. The bones that are most commonly involved are vertebrae, sternum, pelvic bones, ribs, and femurs, and the characteristic radiologic appearance is osteoblastic but it can rarely present with predominantly osteolytic appearance [3]. In bone metastases, pathologic activation of both osteoblasts and osteoclasts are present and the dominance is influenced by the specific interaction of tumor with the bone environment. In fact, the markers of bone resorption are elevated in patients with bone metastases from prostate cancer to a greater degree than bone metastases from any other malignancies [3, 4]. Hence
2 IJCRI 2011;2(9): Rajendiran et al. 17 prostate cancer has strong resorptive component in addition to the element of bone formation and this case profiles an advanced prostate cancer patient with predominant resorptive component resulting in extensive osteolytic metastases. CASE REPORT A 65-year-old African American man with no past medical history presented with intermittent left gluteal pain for three months. He did not have obstructive urinary symptoms, incontinence, back pain, weakness or numbness. He denied any physician evaluation or hospital visit in the last 35 years, as he did not suffer from any major illness and treated himself with overthe-counter medications for minor ailments. Examination findings were normal, except for an illdefined swelling in the left gluteal region and enlarged very hard prostate. His blood test results were normal; except for a highest PSA level of 7242 ng/ml. Computed tomography (CT) imaging of abdomen, pelvis and thorax showed diffuse osteolytic metastases involving the entire spine, ribs and pelvis, and there was an isolated expansile lytic lesion in the left iliac bone (Figures 1, 2). Magnetic resonance imaging (MRI) study of the entire spine showed similar findings but did not show any evidence of fracture or dislocation or significant cord compression (Figure 3). Whole body Technetium bone scan showed diffuse reduce uptake (cold spots) involving several ribs and vertebrae suggestive of extensive osteolytic activity, along with mild irregular uptake suggestive of minimal osteoblastic component (Figure 4). Prostate biopsy revealed adenocarcinoma with a Gleason score of (4 + 3 = 7) which is associated with unfavorable outcome. Serum protein electrophoresis with immunofixation showed a non-quantifiable M spike. Patient was advised biopsy of the iliac bone lesion and bone marrow, but he refused. As he did not have any evidence of multiple myeloma or other malignancy, he was presumptively diagnosed to have metastatic prostate adenocarcinoma with diffuse osteolytic metastases. He was treated with bicalutamide, leuprolide and zoledronic acid (ZA), along with palliative radiotherapy to the left iliac bone lesion. He received 3500 cgy total dose radiation in 14 fractions (250 cgy dose per fraction) to the left superior pelvis and sacroiliac joint. After one year of therapy, his PSA has normalized at 0.66 ng/ml and he was asymptomatic. Posttreatment CT scan of pelvis showed considerable regression of left iliac lytic bone lesion (Figure 5). MRI spine showed significant resolution of lytic lesions with mild residual lesions involving several ribs and vertebrae, and no new lesions were detected. Figure 1: CT scan of the pelvis shows lytic lesion in the left iliac bone (arrow). DISCUSSION In the literature, there are very few reported cases Figure 2: Non-contrast CT scan of the entire spine shows diffuse multiple osteolytic lesions.
3 IJCRI 2011;2(9): Rajendiran et al. 18 Figure 5: Post-treatment CT scan of the pelvis shows significant partial resolution of left iliac bone lesion. Figure 3: MRI scan of the entire spine without contrast shows vertebral bony lesions with no cord compression or fracture. Figure 4: Technetium-bone scan shows diffuse reduce uptake (cold spots) involving several ribs and vertebrae interspersed with mild irregular uptake suggestive of predominantly diffuse osteolytic activity (right forearm is injection site). of osteolytic metastases from prostate cancer and osteolytic lesions have strong resorptive component which increases the propensity for skeletal related events [5, 6, 7]. Our patient had diffuse osteolytic metastases in the pelvis and spine but he did not develop disabling skeletal complications and he responded well to ZA, hormonal and palliative radiation therapy. Post-treatment imaging studies confirmed significant regression of osteolytic lesions with no new metastatic bone lesions. Recent research studies have focused on the pathogenesis of bone metastasis to identify potential targets for therapeutic intervention. Metastatic tumor cells in the bone dysregulate the coordinated relationship between osteoclastic and osteoblastic functions and promote tumor cell proliferation and bone destruction with the aid of various cytokines and growth factors [8, 9]. The pathologic dominance determines the common radiographic patterns of bone lesions that vary from predominantly osteolytic, as commonly seen in breast cancer and multiple myeloma, to predominantly osteoblastic, as commonly seen in prostate cancer [3, 4, 8, 9]. Research studies have demonstrated that the markers of bone resorption are elevated to a greater degree in patients with bone metastases from prostate cancer than bone metastases from any other malignancies. The expression of IL-1, IL-6, RANKL (receptor activator of nuclear factor κb ligand) and parathyroid hormone related peptide by prostate cancer cells promote osteoclastogenesis. The traid of RANKL /RANK/ osteoprotegerin has been identified as a key regulator of bone resportion. RANKL expressed on marrow stromal cells and osteoblasts is a potent inducer of osteoclast formation, and its binding to RANK receptors on osteoclast precursors trigger differentiation and activation. This process is controlled by osteoprotegerin, a decoy receptor for RANKL, which inhibits osteoclast differentiation and
4 IJCRI 2011;2(9): Rajendiran et al. 19 resorption. The presence of osteoclast-stimulating cytokines such as IL-6, IL-1, IL-17 and colonystimulating factors in the bone microenvironment also induces osteoclast function [9]. The release of growth factors (like TGF- β) secondary to bone lysis promotes cancer cell growth and endures a vicious cycle of tumor growth and bone destruction. We speculate that our patient had predominant pathologic osteoclast activity in the metastatic bone lesions resulting in osteolytic radiographic appearance. Bone is a common site for metastasis in patients with prostate adenocarcinoma and results in significant disabling complications like pathological fracture, spinal cord compression, severe bone pain and impaired mobility, unless intervened [9]. Despite all the novel diagnostic and therapeutic methods, advanced prostate cancer disease remains incurable, and the median survival between the diagnosis of a clinically evident metastasis in bones and death is approximately 3 5 years [8]. Treatment is mainly palliative and supportive therapy plays an important role in the prevention of skeletal complications and reducing bone pain in these patients. A range of options are available for treating skeletal metastases, including antineoplastic therapies that are directed at the tumor cells and other supportive or palliative therapies aimed at attenuating the skeletal complications, including bisphosphonates, radiotherapy, radiopharmaceuticals, surgery, vertebroplasty and kyphoplasty [4]. Zoledronic acid, an aminobisphosphonate, exerts potent inhibition of osteoclast adherence or activity and enhances osteoclast apoptosis; and it is currently used to prevent skeletal complications from bone metastases [3, 4, 9]. The NCCN (National Comprehensive Cancer Network) recommends the use of ZA every three to four weeks in men with castrateresistant prostate cancer and bone metastases. Other bisphosphonates like pamidronate and clodronate did not demonstrate an overall treatment benefit relative to placebo in these patients with advanced disease [4]. ZA (4 mg intravenously every three to four weeks) was approved by United States Food and Drug Administration (US FDA) to treat men with prostate cancer metastatic to bone and with disease progression despite first-line hormone therapy, whereas outside the US, ZA is approved for use in patients with bone metastasis from prostate cancer regardless of their hormone responsive status [4]. Randomized trial showed patients treated with ZA experienced fewer SREs (33% Vs 44%; p=0.021) and a prolonged time interval to the occurrence of the first SRE (not reached vs. 321 days; p=0.011). Extended study confirmed the initial data and showed that the treatment group achieved a significant reduction in the incidence of skeletal complications (38% vs. 49%; p=0.028) [4, 9]. Due to the presence of extensive osteolytic metastases in our patient, he was started on zoledronic acid along with ADT to prevent disabling skeletal complications. This case emphasizes the importance of regular screening for prostate cancer. The 5-year relative survival among men with localized prostate cancer or with just regional spread is 100%, compared with 31.9% among those diagnosed with distant metastases [1]. Although the mortality risk reduction with prostate cancer screening is small and controversial, the early detection and treatment can reduce morbidity and prevent skeletal complications which adversely affect the quality of life. The present guidelines emphasize the need for men to have sufficient information regarding the risks and benefits of screening and treatment to make an informed and shared decision [2]. For men who decide to be screened, it is suggested to begin at age 50 in average risk white men and at age in black men, men with a positive family history, and men who are known or likely to have BRCA1 mutation (Grade 2B). The screening is recommended to be continued until age (75 years) or comorbidites limit life expectancy to less than 10 years or the patient decides against further screening (Grade 2B). Stopping screening at age 65 may be appropriate if the PSA level is less than 1.0 ng/ml [2]. CONCLUSION Early detection and supportive treatment plays an integral role in reducing morbidity and preventing skeletal complications associated with bone metastases from prostate cancer. To our knowledge, this is the first reported case of prostate adenocarcinoma presenting with very high levels of PSA and extensive osteolytic metastases. Author Contributions Govarthanan Rajendiran Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Linda Green Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Gurdeep Chhabra Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Guarantor The corresponding author is the guarantor of submission. Conflict of Interest Gurdeep Chhabra, Hemato-oncologist, is a speaker for
5 IJCRI 2011;2(9): Rajendiran et al. 20 Novartis. Other authors have no financial interests or conflict of interests. Copyright Govarthanan Rajendiran et al. 2011; This article is distributed under the terms of Creative Commons attribution 3.0 License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see /copyright-policy.php for more information.) REFERENCES 1. Ries, LAG, Melbert, D, Krapcho, M, et al (Eds). SEER Cancer Statistics Review, , National Cancer Institute, Bethesda, MD Available at based on November 2006 SEER data submission. 2. Hoffman RM. Screening for prostate cancer. Uptodate v18.3. Available at 3. Mundy GR. Metastasis to bone: Causes, consequences, and therapeutic opportunities. Nat Rev Cancer. 2002;2: Smith MR, Brown GA, Saad F. New opportunities in the management of prostate cancer-related bone complications. Urol Oncol Semin Ori. 2009;27(suppl):1s-20s. 5. Migita T, Maeda K, Ogata N. A case of prostate cancer associated with osteolytic bone metastases. Hinyokika Kiyo May;45(5): Fukuoka H, Ishibashi Y, Masuda M et al. A case of prostatic carcinoma with osteolytic bone metastases. Hinyokika Kiyo Oct;34(10): Ansari MS, Nabi G, Aron M. Solitary radial head metastasis with wrist drop: a rare presentation of metastatic prostate cancer. Urol Int. 2003;70(1): Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab Apr;22(2): Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J natl Cancer Inst. 2002;94:
Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S
Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia Meet Mr. S 74 M admitted for back pain X-ray: sclerotic lesions along spine PSA 800 Nuclear Medicine Bone Scan 1
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More information.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationThe Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationPathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
More informationArie Barlev, PharmD, MS; Xue Song, PhD; Boris Ivanov, MS; Vidya Setty, MPH, MBA; and Karen Chung, PharmD, MS
RESEARCH Payer Costs for Inpatient Treatment of Pathologic Fracture, Surgery to Bone, and Spinal Cord Compression Among Patients with Multiple Myeloma or Bone Metastasis Secondary to Prostate or Breast
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationWhat You Need to Know for Better Bone Health
What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationIn Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
More informationBone Metastases in Advanced Prostate Cancer
Bone Metastases in Advanced Prostate Cancer a report by Fred Saad, MD, FRCS Centre Hospitalier de l Université de Montréal, Hôpital Notre-Dame, Montreal, Canada DOI: 1.17925/OHR.25...1v Fred Saad, MD,
More informationBone Disease in Myeloma
Bone Disease in Myeloma Boston, Massachusetts Saturday, July 26, 2008 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationDevelopment of Bone Metastases in Men With Prostate Cancer
Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant
More informationOPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.
Title of the poster Authors Sheffield Cancer Research Centre University of Sheffield OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Dr Penelope Ottewell Background
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationRadiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015
Radiotherapy in Plasmacytoma and Myeloma David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015 Contents Indications for radiotherapy: Palliation in Multiple Myeloma Solitary Bone Plasmacytoma
More informationContinuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
More informationManagement of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
More informationCase Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
More informationRadiologic Diagnosis of Spinal Metastases
September 2002 Radiologic Diagnosis of Spinal Metastases Natalie J. M. Dailey, Harvard Medical Student Year III Our Patient s Presenting Story 70 year old male Presents to the hospital for laparascopic
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationRT for Recurrent, Bulky, and Chemotherapy-Refractory Follicular Lymphoma: A Treatment Modality for Both Alleviating Symptoms and Potential Cure
RT for Recurrent, Bulky, and Chemotherapy-Refractory Follicular Lymphoma: A Treatment Modality for Both Alleviating Symptoms and Potential Cure Case Number: RT2009-04(M) Potential Audiences: Intent Doctor,
More informationA Diagnostic Chest XRay: Multiple Myeloma
Daniela Marinho Tridente, VI FCMSCSP October 2013 A Diagnostic Chest XRay: Multiple Myeloma Daniela Marinho Tridente, VI FCMSCSP Our Learning Agenda Introduction of our patient His imaging data and findings
More informationTreatment of Myeloma Bone Disease
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationProstate Cancer with Bone Metastasis: the Consideration of Radiotherapy
Prostate Cancer with Bone Metastasis: the Consideration of Radiotherapy Case Number: RT2009-19(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present a case
More informationCancer Related Issues: Bone Metastases
Cancer Related Issues: Bone Metastases Bronwyn Long, RN, DNP, ACHPN, AOCNS Updated from Hawkins, R. Cancer Related Issues: Bone Metastasis. Pittsburgh, PA: Hospice and Palliative Nurses Association; 2010:
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationGENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.
GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationHEALTH NEWS PROSTATE CANCER THE PROSTATE
HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationCase Number: RT2009-114(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Extensive-Stage Small Cell Lung Cancer Post Full-Course Chemotherapy with Residual Locoregional Cancer Disease: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-114(M) Potential
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationMetastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
More informationMultiple Myeloma. Abstract. Introduction
Multiple Myeloma Abstract Multiple Myeloma is a plasma cell cancer that causes an overproduction of plasma cells. Multiple Myeloma is a difficult disease to diagnosis because symptoms might not be present
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationMultiple Myeloma s Impact on Bones
A Report about Multiple Myeloma s Impact on Bones BONE HEALTH IN FOCUS The significance of bone health in patients with Multiple myeloma Today s patient with cancer faces a daunting amount of information.
More informationBone lesions due to metastatic disease undermine
Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy Allan Lipton Several cancers, including those originating in the breast, prostate, and lung, exhibit a propensity to metastasize
More informationPeople Living with Cancer
Patient Guide ASCOInformation for People Living with Cancer HORMONE THERAPY FOR ADVANCED PROSTATE CANCER Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationTable 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
More informationA RepoRt About Prostate CanCer s ImPaCt on Bones
A Report about Prostate Cancer s Impact on Bones BONE HEALTH IN FOCUS The significance of bone health in patients with prostate cancer Today s patient with cancer faces a daunting amount of information.
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationMultiple Myeloma with Pathologic Fracture: the Role and Treatment Consideration of RT
Multiple Myeloma with Pathologic Fracture: the Role and Treatment Consideration of RT Case Number: RT2009-37(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationCLODRONATE FOR TREATMENT OF BONE METASTASES IN HORMONE REFRACTORY PROSTATE CANCER
Clinical Urology CLODRONATE IN BONE METASTASES International Braz J Urol Vol. 29 (3): 228-233, May - June, 2003 Official Journal of the Brazilian Society of Urology CLODRONATE FOR TREATMENT OF BONE METASTASES
More informationGeneral Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationTHE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE
THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE Summary of Presentations from the Bayer Healthcare Symposium, held at the 29 th Annual EAU
More informationNewly Diagnosed Prostate Cancer: Understanding Your Risk
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationRecognizing and Understanding Pain
Because multiple myeloma is a cancer involving the bone marrow, a common myeloma symptom is bone pain. But the good news is that most pain can be managed. This resource can help you better understand pain
More informationAdvanced Prostate Cancer Treatments
Advanced Prostate Cancer Treatments Guest Expert: Kevin, DO Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with
More informationMETASTASES TO THE BONE
RADIATION THERAPY FOR METASTASES TO THE BONE Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY WHAT ARE BONE METASTASES? Cancer that starts
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationClinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationProstate Cancer In-Depth
Prostate Cancer In-Depth Introduction Prostate cancer is the most common visceral malignancy among American men. In the year 2003, there are expected to be 220,000 new cases and nearly 29,000 deaths in
More informationPROSTATE CANCER NOT TO BE TAKEN LIGHTLY!
PROSTATE CANCER NOT TO BE TAKEN LIGHTLY! Observations of Wichita Chapter Us TOO Members through research, reading p2p (physician to patient) exchanges, or having attended or reviewed recordings of presentations
More informationSIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer
SIGNPOSTS Along the Pathway of Prostate Cancer Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer Your journey is unique like you. Signposts along the pathway can show you where you
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationTHERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS
438 J App Pharm 04(03): 438-452 (2011) Qasim et al., 2011 ORIGINAL ARTICLE THERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS Saima
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationFour Important Facts about Kidney Cancer
Volume Article.13-11 Publish Date: 24th June 2013 Author(s): MPUH - CRS Team Four Important Facts about Kidney Cancer ARTICLE hhh Muljibhai Patel Urological Hospital (MPUH) Centre For Robotic Surgery (CRS)
More informationSecondary breast cancer in the bone
Secondary breast cancer in the bone This booklet is for anyone who has been diagnosed with secondary breast cancer in the bone. It describes what secondary breast cancer in the bone is, what the symptoms
More informationAdvanced prostate cancer
1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer? What do my test results mean? What are my treatment
More informationDIAGNOSIS OF PROSTATE CANCER
DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationSpine University s Guide to Vertebral Osteonecrosis (Kummel's Disease)
Spine University s Guide to Vertebral Osteonecrosis (Kummel's Disease) 2 Introduction Kummel's disease is a collapse of the vertebrae (the bones that make up the spine). It is also called vertebral osteonecrosis.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationAdvanced prostate cancer
Diagnosis Helpline 0800 074 8383 prostatecanceruk.org 1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer?
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More information